Pfizer Inc. (ETR:PFE)

Germany flag Germany · Delayed Price · Currency is EUR
22.28
+0.39 (1.76%)
At close: Dec 5, 2025
-7.26%
Market Cap 127.22B
Revenue (ttm) 53.69B
Net Income (ttm) 8.41B
Shares Out n/a
EPS (ttm) 1.48
PE Ratio 15.13
Forward PE 8.75
Dividend 1.53 (6.95%)
Ex-Dividend Date Nov 7, 2025
Volume 39,207
Average Volume 52,759
Open 22.01
Previous Close 21.90
Day's Range 21.98 - 22.30
52-Week Range 18.57 - 26.54
Beta 0.43
RSI 57.23
Earnings Date Feb 3, 2026

About Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]

Sector Healthcare
Founded 1849
Employees 81,000
Stock Exchange Deutsche Börse Xetra
Ticker Symbol PFE
Full Company Profile

Financial Performance

In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.

Financial numbers in USD Financial Statements

News

Do These 3 Healthcare Stocks Need a Checkup?

Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.

9 hours ago - The Motley Fool

Smart Money Is Betting Big In PFE Options

Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer (NYSE: PFE) revealed 20 unusual trades. Delving into the details, we found 35% of traders w...

13 hours ago - Benzinga

2 Headwinds Facing Pfizer Stock Going Into 2026

There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.

15 hours ago - The Motley Fool

Pfizer: The Market Is Still Wrong About It

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read my latest analysis of PFE stock.

16 hours ago - Seeking Alpha

PFE June 2027 Options Begin Trading

Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the June 2027 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is th...

2 days ago - Nasdaq

17 dividend-stock bargains from a value manager with a stellar track record

John Buckingham, editor of the Prudent Speculator, reminds investors to be “willing to stomach volatility.”

3 days ago - Market Watch

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

3 days ago - Nasdaq

PFE: Citigroup Reinstates Neutral Rating with a $26 PT | PFE Stock News

PFE: Citigroup Reinstates Neutral Rating with a $26 PT | PFE Stock News

3 days ago - GuruFocus

Pre-Market Most Active for Dec 2, 2025 : INTC, EB, TSLL, TQQQ, NVDA, IREN, IBIT, SMFG, NIO, T, INVH, PFE

The NASDAQ 100 Pre-Market Indicator is up 119 to 25,461.85. The total Pre-Market volume is currently 97,034,402 shares traded.The following are the most active stocks for the pre-market session: Intel...

3 days ago - Nasdaq

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam Pharmaceuticals.

3 days ago - Investor's Business Daily

2 Top Dividend Stocks to Buy Now and Hold For a Decade

Pfizer's strategy that will help it rebound from recent struggles is in full motion. It says a lot that the company continues to grow its dividend through tough times.

3 days ago - The Motley Fool

Pfizer (PFE) Coverage Resumed by Citi with 'Neutral' Rating

Pfizer (PFE) Coverage Resumed by Citi with 'Neutral' Rating

4 days ago - GuruFocus

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.

4 days ago - Investopedia

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Memo also reportedly mentions vaccines for flu and pneumonia.

4 days ago - Market Watch

Pfizer (PFE) Part of UK-US Drug Pricing Agreement

Pfizer (PFE) Part of UK-US Drug Pricing Agreement

4 days ago - GuruFocus

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, D...

4 days ago - Business Wire

2 Undervalued, High-Quality Companies to Buy Now and Hold Forever

Drug companies face fairly normal industry dynamics that can leave them unloved on Wall Street over short periods of time. Pfizer is facing a patent cliff and is making a big move to revamp its drug p...

5 days ago - The Motley Fool

This 7% Yielder Could Be a Top AI Play

A looming patent cliff in which Pfizer will lose patent exclusivity to a handful of drugs has combined with cratering revenue from COVID-19 treatments to drive Pfizer shares down 50% since 2022. Pfize...

5 days ago - The Motley Fool

3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio

Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-t...

5 days ago - The Motley Fool

Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters

Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in th...

5 days ago - Seeking Alpha

Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December

This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Most of the dividend increases announced in the last two ...

6 days ago - Seeking Alpha

After Hours Most Active for Nov 28, 2025 : HBI, NVDA, SNAP, NEOG, MOS, INTC, AAPL, PFE, QQQ, CCL, AVTR, MSFT

The NASDAQ 100 After Hours Indicator is down -1.79 to 25,433.1. The total After hours volume is currently 95,876,785 shares traded.The following are the most active stocks for the after hours session:...

7 days ago - Nasdaq

8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills

Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project n...

7 days ago - Seeking Alpha

8 Dividend Stocks Every Investor Should Consider

Dividend investing isn't just about yield -- payout ratio and growth potential matter too. Several of these companies have increased dividends for decades without interruption.

7 days ago - The Motley Fool

Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?

PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.

8 days ago - Nasdaq